about
Hepatitis C virus infection in the immunocompromised host: a complex scenario with variable clinical impactHERG K+ channels activation during beta(1) integrin-mediated adhesion to fibronectin induces an up-regulation of alpha(v)beta(3) integrin in the preosteoclastic leukemia cell line FLG 29.1.Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis.Role of microRNA profile modifications in hepatitis C virus-related mixed cryoglobulinemiaHepatitis C virus lymphotropism: lessons from a decade of studies.HCV-related liver and lymphoproliferative diseases: association with polymorphisms of IL28B and TLR2.Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment.Virus-driven autoimmunity and lymphoproliferation: the example of HCV infection.Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy.Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review.Virological and Clinical Response to Interferon-Free Regimens in Patients with HCV-Related Mixed Cryoglobulinemia: Preliminary Results of a Prospective Pilot Study.Autoimmunity and lymphoproliferation markers in naïve HCV-RNA positive patients without clinical evidences of autoimmune/lymphoproliferative disorders.IgG3 subclass: A possible trigger of mixed cryoglobulin cascade in hepatitis C virus chronic infection.Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies.Assessment of free light chains in HCV-positive patients with mixed cryoglobulinaemia vasculitis undergoing rituximab treatment.Free light chains: Eclectic multipurpose biomarker.Impact of immunogenetic IL28B polymorphism on natural outcome of HCV infection.Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study.Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study.Modifications of plasma platelet-activating factor (PAF)-acetylhydrolase/PAF system activity in patients with chronic hepatitis C virus infection.Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fcγ receptors.Effect of chronic hepatitis C virus infection on inflammatory lipid mediators.Association between persistent lymphatic infection by hepatitis C virus after antiviral treatment and mixed cryoglobulinemia.Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation.Detection of WA B cells in hepatitis C virus infection: a potential prognostic marker for cryoglobulinemic vasculitis and B cell malignancies.Detection of bcl-2 rearrangement in mucosa-associated lymphoid tissue lymphomas from patients with hepatitis C virus infection.149 HCV AND lymphoma: Genetic and epigenetic factors.Developmentally regulated expression of the mouse homologues of the potassium channel encoding genes m-erg1, m-erg2 and m-erg3.Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection: a predictor of spontaneous viral clearance and sustained virological response.Hepatitis C-associated B-cell non-Hodgkin lymphomas: the emerging role of miRNA-26b.Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study.Can BAFF promoter polymorphism be a predisposing condition for HCV-related mixed cryoglobulinemia?HCV infection, malignancy, and liver transplantationLongitudinal evaluation of liver stiffness and outcomes in patients with chronic hepatitis C before and after short- and long-term IFN-free antiviral treatmentLong-lasting persistence of large B-cell clones in hepatitis C virus-cured patients with complete response of mixed cryoglobulinaemia vasculitis
P50
Q22299128-4FFAD97C-016F-4429-9DB1-740BF558E3C6Q31570866-AFAFD87B-3F6D-40A8-8869-CB94B3BE7668Q34401717-56EFE4EE-030E-4731-8094-EDE8643103CDQ34708468-B9C44A9F-83A2-4D20-9041-3668DB098F0AQ36971058-95BCA58F-DE63-4B52-ACCC-AF02D29F51B9Q37437190-037C7335-ED2D-4B41-BC14-2F07E0102246Q37532286-45538460-5FEB-4858-A8C9-787D902CFA0FQ38298448-12A2DC24-C13F-4853-B4E5-65FAA912A592Q38393228-BA365655-61CF-4BAF-B537-343F18E584F7Q38511178-3542BCAE-E7D7-4E0F-823F-D504B7885E97Q38725506-75B851D2-41E8-4FC0-8AA0-FE27184C3A7FQ39690864-8EB89754-7B3B-43C5-BC19-2E52B44DEA03Q40130837-A520E131-7D18-4D63-B358-84798B4C9932Q41053182-1D92038D-9A7E-4000-B56D-F00141C78549Q41175619-5C6661A3-CE0B-4AFC-BA2B-E5C9D1E4B34AQ41933512-40B41092-6217-4B03-8154-428A798CF239Q42133572-0761942F-224E-4D3B-B0AE-B42CB04D18B2Q42180401-C436D697-F0E8-408D-85AC-32F90C6EE8CFQ42210826-0C3A10C3-E6B3-41F3-B05B-7F2B05CFB16FQ43035003-C9E595B4-826D-4822-AABC-C72F349B6C31Q43036468-2626B6AE-F75F-4CE5-9BFB-7A60135B627CQ43041371-1AFD44BB-5669-4A5A-9E29-6799DD5FF977Q43046687-7F2A5BB0-17E2-4F61-844B-45E871F1E585Q44399985-5C3D20AC-1C34-44D9-BC0A-7DE7B7C0ABABQ45375716-7AD99755-D941-4D9E-84E0-3E696077C371Q45613662-FDE4C0D9-9DEB-4AFC-A062-3F6E18C5C3F5Q45972727-35A7B81B-F300-4DCF-A0D9-EDFE30633637Q48130718-7ED6FD4C-17C3-4E2A-B3D5-20B80E1B5D88Q51849759-BC469346-D289-4C19-913C-D51DC84F1C40Q51866759-72ACC364-357D-495B-BBB4-DBDAE029DFC2Q54268476-72493007-FC4B-457D-A1EE-431159204619Q62029506-0CF15780-D0FF-496E-9174-31D12F12B66AQ62029526-5DE08DFA-5B73-4349-AC0C-105FDBE95D50Q91185803-B231E645-AD61-4DAF-ADD2-7BE55B11E3F4Q91253680-0FBA9D3A-DE84-4CAF-A198-90ABDB2E5006
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Laura Gragnani
@ast
Laura Gragnani
@en
Laura Gragnani
@es
Laura Gragnani
@sl
type
label
Laura Gragnani
@ast
Laura Gragnani
@en
Laura Gragnani
@es
Laura Gragnani
@sl
prefLabel
Laura Gragnani
@ast
Laura Gragnani
@en
Laura Gragnani
@es
Laura Gragnani
@sl
P1053
K-7751-2013
P106
P1153
6603323664
P21
P2798
P31
P3829
P3835
laura-gragnani
P496
0000-0001-6800-9149